Profusa Inc Stock Price, News & Analysis

Profusa (Nasdaq: PFSA) reported third-quarter 2025 results and business highlights on Nov 19, 2025. Key outcomes include a completed reverse recapitalization with NorthView, a company equity value of $155 million, and a manufacturing build-out on track for early 2026 product shipments.

Financing actions lowered net debt from $48 million last quarter to $16 million in 3Q and $14 million as of Oct 31, 2025; the company raised $12 million from a convertible PIPE (with $10 million available) and $7 million from an ELOC (with $93 million available). Cash and cash equivalents were $4 million. Management reiterated potential revenue of $0.5–$2M in 2026, $9–$13M in 2027, and a long-term target of $200–$250M by 2030.

Profusa (Nasdaq: PFSA) outlined a commercialization and revenue roadmap anchored by its Lumee tissue-integrated biosensor platform. The company expects EU commercialization in 2Q 2026 with CE GMED certification anticipated in late 1Q 2026 and projects €600–€800 per procedure and equipment revenue of €30,000–€40,000 per center per year. Profusa stated ~35% European population coverage via intended distributors and forecasted potential revenue of $0.5–$2M in 2026, $9–$13M in 2027, and $200–$250M by 2030.

The company plans US Lumee oxygen launch in 1Q 2027 and EU Lumee glucose in mid-2027, and cited addressable markets and additional analytes that could contribute to 2030 targets.

Profusa (Nasdaq: PFSA) completed key manufacturing milestones and says it is on track to begin product shipments and generate revenue in early Q2 2026 for its Lumee tissue oxygen monitoring systems.

Operational highlights: first sensor production run completed in October 2025 in a new CER; pen production began in October with capacity >2x the pens needed for 2026 targets; patch/reader first production run expected in November 2025; overall manufacturing capacity exceeds 2x the units Profusa says are required to meet 2026 revenue targets. Profusa intends distributor partnerships with AngioPro and Dismeval, covering ~35% of European procedures, and cites a 2025 European CLTI market of >700,000 procedures.

Profusa (Nasdaq: PFSA) announced on October 22, 2025 an expansion of commercial distribution for its Lumee Oxygen platform in Europe via a letter of intent with Angiopro GmbH.

Initial target launch markets are Germany, Benelux, Austria, the United Kingdom, and Scandinavia. Combined with a prior Spain distributor, Profusa estimates distributor channels now cover ~35% of the European Union population. The company cites ~300,000 annual endovascular procedures in Europe and a global addressable market of $10.5B+ across three indications: peripheral artery disease, chronic wounds, and critical limb ischemia.

Profusa (Nasdaq: PFSA) expanded its European commercial footprint for the Lumee Oxygen platform by signing a letter of intent with Angiopro on Oct 15, 2025 to establish logistics and commercialization in Germany, Benelux, Austria, the UK, and Scandinavia.

The deal, together with a previously announced Spain distributor, brings distribution coverage to approximately 35% of the EU population. Management cites an estimated $10.5B+ global addressable market across peripheral artery disease, chronic wounds and critical limb ischemia and references ~300,000 annual endovascular procedures in Europe as an initial target opportunity.

Profusa (Nasdaq: PFSA) announced on October 7, 2025 a second $1 million investment in digital treasury assets as part of its treasury management strategy to hedge macroeconomic uncertainty. The company said the strategy supports commercial and development plans for its Lumee continuous biochemical monitoring platform and aims to maintain capital for AI-driven digital health initiatives. Profusa noted continued collaboration with Ascent Partners Fund, which funded an additional $2 million tranche to establish a low-cost, capital-efficient Bitcoin treasury approach the company views as a digital store of value. Management framed the purchases as a foundation for progressing commercial and clinical programs.

Profusa (NASDAQ:PFSA), a digital health company, has announced a significant collaboration with Dr. Yann Gouëffic, a leading French surgeon specializing in critical limb threatening ischemia (CLTI). Dr. Gouëffic, along with his FRANCE-PAD network, will adopt Profusa's Lumee™ oxygen monitoring technology for both clinical practice and home monitoring studies.

The collaboration is notable as Dr. Gouëffic and his affiliated practices handle approximately 8% of all CLTI cases in France. Dr. Gouëffic brings over 20 years of experience in endovascular procedures and has authored more than 140 peer-reviewed articles. The partnership aims to advance vascular disease management in Europe, where the endovascular market includes over 300,000 procedures annually.

Profusa (NASDAQ:PFSA), a digital health company, has announced the integration of NVIDIA technology to develop an AI-powered insight portal for continuous biochemistry monitoring. The portal will combine Profusa's Lumee™ oxygen monitoring system with NVIDIA NeMo to enable advanced clinical workflows.

The platform will feature an AI-driven physician portal with capabilities including EMR integration, remote monitoring, and a longitudinal health data graph that combines Profusa biomarkers with various health data sources. The system aims to provide real-time biochemistry monitoring and actionable clinical insights for healthcare providers.

Profusa plans to launch the portal in early 2026 across the European Economic Area (EEA) where CE Mark certification is accepted.

Profusa (NASDAQ:PFSA), a digital health company, announces a new commercial and clinical collaboration with the Department of Vascular Surgery at AZ Sint Blasius Hospital, Belgium. The partnership is led by Dr. Koen Deloose, an internationally recognized vascular surgeon specializing in critical limb ischemia (CLTI).

Dr. Deloose, who treats over 300 CLTI patients annually, has successfully implemented Profusa's Lumee™ Oxygen measurement system for monitoring endovascular revascularization procedures. The technology provides real-time tissue oxygen perfusion metrics crucial for treatment success. Dr. Deloose's modern vascular clinic offers a multidisciplinary approach, combining expertise from diabetic foot specialists, wound care experts, and podiatrists.